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Parkinson’s disease is a common neurodegenerative disorder. In this study, the monoamine oxidase 
inhibitory activity and potential anti-parkinsonian effects of 8-propyl-6H-[1,3]dioxolo[4,5-g]chromen-
6-one (FCS303), a new synthetic coumarin, were evaluated. To do this, we used the reserpine model of 
Parkinson’s disease, an assay of levodopa/carbidopa potentiation, the catalepsy model of haloperidol, 
and an in vitro assay against monoamine oxidase (MAO) activity. Additionally, lipid peroxidation and 
protein carbonyl group quantification was performed in mice brain homogenates previously treated 
with haloperidol. FCS303 inhibited monoamine oxidase B (MAO-B) with an IC50 of 5.46 ± 0.36 µM; 
however, there was no effect on monoamine oxidase A (MAO-A). The oral administration of 
FCS303 led to a significant reversal of hypokinesia in the reserpine model (at 24 h, doses of 100 and  
200 mg/kg) and in the levodopa/carbidopa potentiation assay (at 2 and 24 h, dose of 200 mg/kg). In 
addition, FCS303 (100 mg/kg) showed anti-cataleptic activity against haloperidol. FCS303 (50 mg/kg) 
significantly decreased lipid peroxidation and protein carbonyl quantification. These results suggest that 
FCS303 could present anti-parkinsonian activity related to MAO-B inhibitory activity.
Keywords: Parkinson’s disease. Monoamine oxidase B. Coumarin. Mice. Reserpine. Levodopa. 
Carbidopa. 
INTRODUCTION 
The World Health Organization (WHO) has 
estimated that four million people worldwide suffer 
from Parkinson’s disease (PD) (Philippens, 2008). PD 
is a neurodegenerative disease that is characterized by a 
loss of dopaminergic neurons of the substantia nigra and 
basal ganglia. This leads to alteration in the control and 
coordination of movement. In addition, PD is characterized 
by muscle rigidity, bradykinesia, resting tremor, and 
alterations in balance and walking (Alexi et al., 2000; 
Emborg, 2004). 
Levodopa (L-DOPA) is a symptomatic therapy 
that compensates for the decreased level of dopamine 
(DA). Monoamine oxidase B (MAO-B) inhibitors have 
been widely applied in PD (Foley et al., 2000). Interest in 
MAO-B inhibitors was initially stimulated by the desire 
to elevate the reduced striatal DA concentration, which 
is characteristic of PD. Selegiline and rasagiline are 
selective MAO-B inhibitors that continue to be valuable 
adjunct therapies to L-DOPA for PD (Gershanik, 2015). 
These agents are very useful in the treatment of disease 
symptoms in early stage and improve the response to 
L-dopa in late stage of the disease (Finberg, 2014). 
Due to the activity shown in the central nervous 
system, coumarins have attracted attention in the search for 
new PD treatments. One study evaluated 1,2-Benzopyrone 
(obtained from Hygrophila tyttha Leonard species) and 
found that coumarin was responsible, at least in part, 
for the anxiolytic, anticonvulsant, and sedative effects 
described for this species (Ariza et al., 2007). Other 
coumarins, both natural and modified, have shown 
antidepressant (Vergel et al., 2010) and neuroprotective 
effects (Kang et al., 2005; Epifano et al., 2008). Some 
studies have shown that coumarinic compounds inhibit 
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MAO-B (Matos et al.,  2004; Matos et al.,  2009; 
Matos et al., 2010; Matos et al. 2013). 
In this study, we evaluated the MAO inhibitory 
activity and potential anti-parkinsonian effects of 8-propyl-
6H-[1,3]dioxolo[4,5-g]chromen-6-one (FCS303), a new 
coumarin whose spectroscopic data is described below.
MATERIAL AND METHODS
Drugs and chemicals
FCS303 was synthesized by the Pechmann reaction 
(Potdar, Mohile, Salunkhe, 2001), in which coumarin was 
obtained by condensation of sesamol with ethyl butyryl 
acetate in the presence of sulphuric acid. The infrared and 
1H/13C magnetic resonance spectra led to the elucidation 
of the structure of 8-propyl-6H-[1,3]dioxolo[4,5-g]
chromen-6-one (Figure 1). FCS303 is an amorphous 
brown powder, with melting point range of 147-149 ºC, 
and a molecular weight of 232 g/mol. EI-MS m/z (rel. 
int.) 232 (96), 217 (5), 204 (12), 189 (20), 176 (100), 175 
(90), 159 (15), 145 (3), 131 (7), 115 (5), 103 (6), 89 (10); 
1H NMR (200 MHz, CDCl3) : 6.97 (1H, s, H-5), 6.81 
(1H, s, H-8), 6.13 (1H, s, H-3), 6.05 (1H, d, J=3.2 Hz, 
O-CH2-O), 2,64 (2H, t, H= 7.9 Hz, H-4a), 1.70 (2H, m, 
H-4b), 1.03 (3H, t, J= 7.5 Hz, H-4c; 13C NMR (75 MHz, 
CDCl3) d : 162.1 (s, C-2), 113.2 (d, C-3), 151.8 (s, C-4), 
104.9 (d, C-5), 144.5 (s, C-6), 152.6 (s, C-7), 97.8 (d, C-8), 
144.8 (s, C-9), 116.0 (s, C-10), 101.9 (t, O-CH2-O), 37.1 
(t, C-4a), 21.8 (t, C-4b), 13.5 (q, C-4c).
Others drugs and reagents were used in the 
experimental procedures, including reserpine, selegiline, 
L-DOPA, carbidopa, clorgiline and iproniazide which were 
supplied by Sigma-Aldrich. Haloperidol (Janssen Cilag®) 
and a MAO kit (Molecular Probes®) were also used.
In vitro assay of human monoamine oxidase 
(hMAO) isoform activity
The effects of FCS303, clorgiline, selegiline and 
iproniazide on human monoamine oxidase (hMAO) 
isoform enzymatic activity were evaluated using a 
fluorimetric method following the experimental protocol 
previously described by Yáñez et al. (2006). Briefly, several 
concentrations of FCS303, and recombinant hMAO-A or 
hMAO-B in required amounts adjusted to obtain the same 
reaction velocity, were incubated with 0.1 mL of sodium 
phosphate buffer (0.05 M, pH 7.4) at 37 °C for 15 min in 
a flat, black-bottomed 96-well microtest plate in the dark 
fluorimeter chamber. The experimental conditions were: 
hMAO-A, 1.1 mg protein; specific activity, 150 nmol 
p-tyramine oxidized to p-hydroxyphenylacetaldehyde/min/
mg protein; hMAO-B, 7.5 mg protein; specific activity, 
22 nmol p-tyramine transformed/min/mg protein. 
After the incubation, the reaction was started when 
200 µM Amplex® Red reagent, 1 U/mL horseradish 
peroxidase, and 1 mM p-tyramine were added. The 
production of hydrogen peroxide and, subsequently, of 
resorufin was quantified in a multi-detection microplate 
fluorescence reader (FLX800TM, Bio-Tek® Instruments, 
Inc., Winooski, VT, USA) at 37 °C, based on the 
fluorescence generated (excitation: 545 nm, emission: 
590 nm) over a period of 15 min , in which the fluorescence 
increased linearly. Simultaneously, control experiments 
were performed replacing the coumarin analogue or 
reference inhibitors (clorgiline, selegiline and iproniazide) 
with suitable dilutions of the vehicles. The capacity of the 
tested drugs to modify the fluorescence generated in the 
mixture by directly reacting with Amplex® Red reagent or 
any non-enzymatic inhibition was determined by adding 
coumarin analogue and reference solutions containing 
only the Amplex® Red reagent in a sodium phosphate 
buffer. The specific fluorescence emission was calculated 
after subtraction of the background activity, which was 
determined in vials where all reagents were preserved, 
except the hMAO isoforms, which were replaced by a 
sodium phosphate buffer solution.
In vivo assays
Animals
Male ICR mice, weighing between 25 and 30 g, 
from the Department of Pharmacy, Faculty of Science, 
Universidad Nacional de Colombia, were used in this 
study. The animals were housed under standard laboratory 
conditions, maintained in 12-hour light-dark cycles and 
at room temperature (22 ± 1°C), with food and water 
available ad libitum.
Non-reserpinized mice 
Mice that did not previously receive reserpine 
were dosed with compound FCS303 (50, 100, and 
FIGURE 1 - Structure of 8-propyl-6H-[1,3]dioxolo[4,5-g]
chromen-6-one (FCS303).
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200 mg/kg), selegiline (10 mg/kg), or vehicle by oral 
(p.o.) administration. The pharmacological effect was 
evaluated at 1.5 and 23.5 h after administration. This test 
was performed to observe the results of the administration 
of selegiline and compound FCS303 in normal mice. 
Model of reserpine
The experimental protocol described by Tadaiesky, 
Andreatini and Vital (2006) was followed, with some 
modifications, such as reserpine dose (3 mg/kg) and 
evaluation time (2 h and 24 h). The mice were dosed with 
3 mg/kg reserpine by intraperitoneal (i.p.) administration. 
Se legi l ine  (10  mg/kg) ,  FCS303 (50 ,  100 ,  and 
200 mg/kg), or vehicle were administered orally 30 min 
later. Locomotor activity was evaluated using the open-
field test, at 2 and 24 h after reserpine administration. Each 
animal was placed in the center of the open-field test, and 
the number of squares crossed was counted for a duration 
of 5 min. The vehicle used comprised 15% glycerol, 15% 
propylene glycol, and distilled water in sufficient quantity 
to make up 100%. 
Potentiation of the effect of L-DOPA/carbidopa in 
mice pre-treated with reserpine
Reserpine (3 mg/kg) was injected i.p. into the 
animals 30 min before the p.o. administration of compound 
FCS303 (100 and 200 mg/kg), selegiline (10 mg/kg), or 
vehicle. L-DOPA plus carbidopa (100 and 10 mg/kg, 
respectively) were administrated i.p. 30 min later to all 
treatment groups. Locomotor activity was evaluated in the 
open-field test for a duration of 5 min, at 2 and 24 h after 
administration of reserpine. 
Anti-cataleptic activity
Catalepsy caused by haloperidol (Kikuchi et al., 
1997; Schmidt et al., 2002; Wei, Chen, 2009) manifests as 
a prolonged stay of both forepaws in an atypical position 
on a horizontal bar. Haloperidol (3 mg/kg) was injected 
i.p. into the animals 30 min after the administration of 
compound FCS303 (100 mg/kg, p.o.), L-DOPA/carbidopa 
(400 mg/kg/40 mg/kg; p.o.), or vehicle (p.o.). The reversal 
of catalepsy was evaluated for a period of 2 min at 60 min 
after administration of treatments.
Antioxidant activity ex vivo
Mice were dosed daily for 10 days with FCS303 
(50 mg/kg, p.o.), L-DOPA/carbidopa (400 mg/kg/ 
40 mg/kg, p.o.), or vehicle (p.o.), 30 min before 
haloperidol (1 mg/kg, i.p.) administration. Animals 
were killed by decapitation, and the brains were rapidly 
removed, washed (KCl 1%), and dissected on an ice-cold 
plate. Homogenates were obtained by homogenization of 
tissue in 50 mM Tris–HCl buffer (pH 7.4). Homogenates 
were centrifuged (10000 rpm for 10 min at 4 °C). The 
final supernatant were stored at -20 °C. The protein 
content of each sample was determined by the Bradford 
method. 
Index of lipid peroxidation in brain homogenates
This assay followed the protocol described by 
Hijova, Nistiar and Sipulova (2005). As such, 50 µL of 50 
mM phosphate buffer (pH 7.4) and 1 mL trichloroacetic 
acid (10%) were added to brain homogenate (450 µL), 
which was then centrifuged at 1850 xg for 10 min at 4°C. 
Next, 1 mL of thiobarbituric acid (0.67%) was added to 
1 mL of supernatant. This mixture was heated to 92°C 
for 30 min, and then cooled in an ice bath (4°C) before 
the absorbance was measured at 532 nm. The results 
are expressed as thiobarbituric acid reactive substances, 
TBARS (mmol/mL/mg), of tissue protein. 
Quantification of protein carbonyl groups 
Quantification of protein carbonyl groups was 
performed using the technique of Levine et al. (1990), 
and following the protocol described by Baltacioglu et al. 
(2008). Briefly, 250 μL of 2 M HCl or 250 µL of 10 mM 
2,4-dinitrophenylhydrazine (DNPH) was added to brain 
homogenate (50 µL) for the blank or sample, respectively. 
The samples were left in the dark at room temperature for 
1 h and vigorously stirred every 15 min. Next, 500 µL of 
trichloroacetic acid (20%) was added. The samples were 
kept in an ice bath for 15 min and then centrifuged at 
11000 rpm for 5 min. The supernatant was removed and 
the pellet was washed three times with 1 mL of ethanol/
ethyl acetate (1:1) solution. After each wash, the sample 
was centrifuged for 7 min at 3000 rpm. The pellet was 
dissolved in 250 µL of 6 M guanidine hydrochloride 
and incubated at 37°C for 10 min. The absorbance was 
determined at 360 nm. The content of carbonyl groups 
was calculated based on the molar extinction coefficient 
of DNPH (ε = 22000 cm-1M-1), and is expressed as nmol/
mg protein (Baltacioglu et al., 2008).
Statistical analysis
Results are expressed as mean ± standard error of 
the mean (SEM). One-way analysis of variance (ANOVA) 
was performed, followed by the Tukey test to determine 
the treatments responsible for the significant differences. 
When variance was not homogeneous, or the data was not 
normally distributed, the Kruskal–Wallis test was applied, 
M. del Pilar Olaya, N. E. Vergel, J. L. López, D. Viña, M. F. Guerrero
Braz. J. Pharm. Sci. 2020;56:e17609Page 4 / 10
followed by the Dunn test. Analyses were performed using 
GraphPad Prism (v. 5.03).
Ethical considerations
The experimental protocols were evaluated and 
approved in a meeting held on October 18, 2011 (Act 
No. 06), by the Faculty of Science Ethics Committee, 
Universidad Nacional de Colombia.
RESULTS AND DISCUSSION 
In this study the new coumarin FCS303, 8-propyl-
6H-[1,3]dioxolo[4,5-g]chromen-6-one (Figure 1), was 
synthesized.
In vitro inhibition of MAO
The ability of the coumarin analogue to inhibit the A 
and B isoforms of MAO was evaluated. The corresponding 
IC50 values and the selectivity indices [IC50 (hMAO-A)]/
[IC50 (hMAO-B)] are shown in Table I.
The FCS303 compound showed selective inhibitory 
activity towards MAO-B, while MAO-A was not 
inhibited, even at the highest tested concentration. The 
new compound and reference inhibitors did not react 
directly with the Amplex Red reagent, which indicates 
that these drugs do not interfere with the measurements.
The structure of FCS303, 8-propyl-6H-[1,3]
dioxolo[4,5-g]chromen-6-one, has substitutions in the 
positions 4, 6, and 7. Previous studies have shown that 
the substitution of hydrogens at positions 4 and 7 seems 
to increase the inhibitory potency of MAO (Santana et al., 
2006). Substitutions at position 3 and/or 4 of the coumarin 
nucleus also contribute to the modulation of the inhibitory 
activity of MAO-B and the A/B selectivity (Gnerre et al., 
2000). In position 7, the steric and lipophilic nature, 
and the electron characteristics, may be decisive in the 
formation of covalent bonds with the flavin ring of the 
flavín adenín dinucleótido (FAD) cofactor (Catto et al., 
2006), which is present in the active site of the enzyme 
MAO. Inhibitors of MAO-B, such as rasagiline and 
selegiline, bind covalently to FAD, specifically the N-5 
flavin (Jenner, 2012; Finberg, 2014).
Altough FCS303 is much less potent than selegiline 
in in vitro hMAO inhibition assay (Table I); their IC50 
is comparable to iproniazide, a drug previously used 
clinically as an antidepressant. Moreover, several 
compounds (including some coumarins) were reported as 
inhibitors of MAO-B with IC50 values in the micromolar 
range (Tripathi et al., 2018). Finally, FCS303 has 
selectivity for hMAO-B, therefore, is reasonable to 




Doses of 50 and 200 mg/kg of compound FCS303 
caused a significant decrease in the locomotor activity at 
23.5 h, in mice that did not previously receive reserpine 
(Figure 2B), compared to the control group. No difference 
was detected at 1.5 h (Figure 2A). Although there are 
differences in locomotor activity induced by FCS303 
between 1.5 h and 23.5 h this could be explained by the 
open field habituation (Haleem, Inam, Haleem, 2015).
In other studies, MAO-B inhibitors, including 
selegiline, have been found to reduce motor activity (Abel, 
1995; Matos et al., 2013). On the other hand, a mechanism 
of action more complex than the inhibition of MAO-B 
could be present. However, the decrease in motor activity 
was an opposite effect to that obtained in the reserpine 
model and in L-DOPA/carbidopa potentiation, in which 
reversal of hypokinesia was observed. This supports the 
possible anti-parkinsonian activity of this coumarin.
TABLE I - In vitro hMAO-A and hMAO-B inhibitory activities of compound FCS303 and reference compoundsa 
Compounds hMAO-A1 (IC50) hMAO-B2 (IC50) Selectivity indexb
FCS303 * 5.46 ± 0.36 µM > 18c
Clorgiline 4.46 ± 0.32 nM 61.35 ± 1.13 µM 0.000073
Selegiline 67.25 ± 1.02 µM 19.60 ± 0.86 nM 3.43
Iproniazide 6.56 ± 0.76 µM 7.54 ± 0.36 µM 0.87
a Each IC50 value is the mean ± standard error of the mean (S.E.M.) from five experiments (n = 5). b hMAO-B selectivity ratios 
[IC50 (hMAO-A)]/[IC50 (hMAO-B)] for inhibitory effects of FCS303 compound and reference inhibitors. c Value obtained under 
the assumption that the corresponding IC50 against hMAO-A is the highest concentration tested (100 µM). * Inactive at 100 μM 
(highest concentration tested). 1 Human monoamine oxidase A (hMAO- A). 2 Human monoamine oxidase B (hMAO- B)
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Reserpine model
Anti-parkinsonian effects were evaluated with 
the reserpine model. After 24 h, the compound FCS303 
showed a statistically significant difference compared to 
the control at doses of 100 and 200 mg/kg (Figure 3B), 
whereas no difference was detected at 2 h (Figure 3A).
FIGURE 2A - Effect of administration of FCS303 (50, 100, 
and 200 mg/kg), control (vehicle 0.1 mL/10 g body weight), 
or selegiline (10 mg/kg) on motor activity in non-reserpinized 
mice. The animals were observed in an open-field test at 1.5 h 
after administration of compound FCS303. n = 7–9. *p < 0.05 
compared to the control group.
FIGURE 2B - Effect of administration of FCS303 (50, 100, 
and 200 mg/kg), control (vehicle 0.1 mL/10 g body weight), 
or selegiline (10 mg/kg) on motor activity in non-reserpinized 
mice. The animals were observed in an open-field test at 23.5 h 
after administration of compound FCS303. n = 7–9. *p < 0.05 
compared to the control group.
FIGURE 3A - Effect of administration of FCS303 (50, 100, 
and 200 mg/kg), control (vehicle 0.1 mL/10 g body weight), 
or selegiline (10 mg/kg) on motor activity in mice treated with 
reserpine (3 mg/kg). The animals were observed in the open-
field test 2 h after administration of reserpine. n = 7–9. *p < 0.05 
compared to the control group.
FIGURE 3B - Effect of administration of FCS303 (50, 100, 
and 200 mg/kg), control (vehicle 0.1 mL/10 g body weight), 
or selegiline (10 mg/kg) on motor activity in mice treated with 
reserpine (3 mg/kg). The animals were observed in the open-
field test 24 h after administration of reserpine. n = 7–9. *p < 
0.05 compared to the control group.
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The effect of reserpine on spontaneous locomotor 
activity is frequently used as a model of the motor 
disturbances associated with PD (Colpaert, 1987; Kaur, 
Starr, 1995; Menzaghi et al., 1997; Tadaiesky et al., 
2006). Several drugs currently on the market were tested 
using this model, supporting its predictive validity 
(Menzaghi et al., 1997; Tadaiesky et al., 2006).
Selegiline and the compound FCS303 caused 
the reversal of hypokinesia in the reserpine model of 
Parkinson’s. This effect was evident because reserpine 
blocks the vesicular monoamine transporter and produces 
a profound and lasting decrease in catecholamine. This 
situation causes depletion of DA in all dopaminergic 
nerve terminals, including the nigrostriatal pathway, 
leading to hypokinesia in animals (Philippens, 2008; 
Matos et al., 2013). MAO inhibitors reduce the enzymatic 
degradation of DA by monoamine oxidase, thus leading 
to an increase in the monoamine (Foley, 2000). DA acts 
on the postsynaptic receptors D1 and D2, which control 
movement (Fisher et al., 2000).
Potentiation of effect of L-DOPA/carbidopa in mice 
pre-treated with reserpine
The doses of FCS303 compound that showed 
the best response in the Parkinson’s reserpine model 
were evaluated. Selegiline and the FCS303 compound 
increased the response of L-DOPA/carbidopa and caused 
a significant reversal of the effects of reserpine, compared 
to the control and the group of levodopa/carbidopa 
(100/10 mg/kg) alone in reserpinized animals (Figures 4A 
and 4B).
The compound FCS303 showed a slightly higher 
response in the levodopa/carbidopa potentiation than 
in the reserpine model. FCS303 showed a statistically 
significant response at 200 mg/kg, and a marked tendency 
towards increased locomotion at 100 mg/kg, compared to 
the control group. This suggests that the compound can 
have a potentiating effect with low doses of L-DOPA/
carbidopa, probably because the MAO-B inhibitor can 
prevent degradation of DA derived from L-DOPA after 
the action of the aromatic L-amino acid decarboxylase in 
the brain. This is an important property because currently, 
one clinical use of selective MAO-B inhibitors such as 
selegiline and rasagiline, is to improve the response to 
L-DOPA at later stages of the disease (Finberg, 2014).
Anti-cataleptic activity
The coumarin analogue FCS303 and L-DOPA/
FIGURE 4A - Effect of administration of levodopa/carbidopa 
(100/10 mg/kg) plus FCS303 (100 and 200 mg/kg), control 
(vehicle 0.1 mL/10 g body weight), or selegiline (10 mg/kg) 
on motor activity in mice pre-treated with reserpine (3 mg/kg). 
The animals were observed in an open-field test 2 h after 
administration of reserpine. n = 7–9. *p < 0.05 compared to the 
control group. +p < 0.05 compared to the group of levodopa/
carbidopa (100/10 mg/kg) alone in reserpinized animals.
FIGURE 4B - Effect of administration of levodopa/carbidopa 
(100/10 mg/kg) plus FCS303 (100 and 200 mg/kg), control 
(vehicle 0.1 mL/10 g body weight), or selegiline (10 mg/kg) 
on motor activity in mice pre-treated with reserpine (3 mg/kg). 
The animals were observed in an open-field test 24 h after 
administration of reserpine. n = 7–9. *p < 0.05 compared to the 
control group. +p < 0.05 compared to the group of levodopa/
carbidopa (100/10 mg/kg) alone in reserpinized animals.
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carbidopa produced a significant decrease in dwell time on 
the horizontal bar at 60 min (Figure 5). No cataleptic effects 
were observed after administration of these treatments (data 
not shown), in mice that did not receive haloperidol.
The reference compounds and the coumarin 
analogue FCS303 showed anti-cataleptic effects in the 
haloperidol model, a dopamine D2 receptor antagonist 
drug. This model can predict the activity of dopaminergic 
and non-dopaminergic drugs in PD. It induces a cataleptic-
like state that can be reversed by such drugs. This condition 
is in some ways analogous to the inability of PD patients 
to initiate movements (Duty, Jenner, 2011).
Antioxidant activity ex vivo
Index of lipid peroxidation in brain homogenates
The brains of mice treated with FCS303 and 
L-DOPA/carbidopa presented lower TBARS levels 
compared to control animals (Figure 6).
Quantification of protein carbonyl groups 
Protein oxidation products were lower in brains 
treated with the compound FCS303 and L-DOPA/
carbidopa, compared to the control animals (Figure 7). 
The levels of TBARS and carbonyl groups in brain 
homogenates of animals that had not undergone any type 
of procedure with haloperidol (untreated) were lower than 
FIGURE 5 - Effect of administration of FCS303 (100 mg/kg), 
control (vehicle 0.1 mL/10 g body weight), or levodopa/
carbidopa (400/40 mg/kg) on catalepsy induced by haloperidol 
(3 mg/kg). Catalepsy in mice was assessed using the horizontal 
bar test 60 min after administration of treatments. n = 8. 
*p < 0.05 compared to the control group.
FIGURE 6 - Effect of administration of FCS303 (50 mg/kg), 
control (vehicle 0.1 mL/10 g body weight), or levodopa/
carbidopa (400/40 mg/kg) on lipid peroxidation in brain 
homogenates of mice treated with haloperidol (1 mg/kg) for 
10 days. n = 8 mice. *p < 0.05 compared to the control group.
FIGURE 7 - Effect of administration of FCS303 (50 mg/kg), 
control (vehicle 0.1 mL/10 g body weight), or levodopa/
carbidopa (400/40 mg/kg) on the oxidation of carbonyl groups of 
proteins in brain homogenates of mice treated with haloperidol 
(1 mg/kg) for 10 days. n = 8 mice. *p < 0.05 compared to the 
control group.
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the levels of the control and treatment groups (Figures 6 
and 7). These results are consistent with several studies 
in which chronic administration of haloperidol was 
associated with increased levels of lipid peroxidation and 
decreased levels of reduced glutathione and antioxidant 
enzymes (catalase and superoxide dismutase), leading 
to oxidative stress (Bishnoi, Chopra, Kulkarni, 2006; 
Bishnoi, Chopra, Kulkarni, 2007). Nevertheless, FCS303 
offered a significant protective effect compared to the 
control animals, probably because the blockade of D2 
receptors by haloperidol resulted in increased dopamine 
turnover. This, in turn, could have conceivably lead to an 
increased production of hydrogen peroxide and other toxic 
dopamine metabolites, resulting in increased oxidative 
stress (Naidu, Singh, Kulkarni, 2003; Singh et al., 2003). 
Inhibitors of MAO-B would be predicted to reduce 
oxidative stress by reducing H2O2 production, thus 
functioning as neuroprotective agents (Foley et al., 2000).
CONCLUSION
According to the current study, it could be concluded 
that the synthetic coumarin FCS303 (8-propyl-6H- [1,3] 
dioxolo [4,5-g] chromen-6-one) has interesting properties, 
such as selective inhibitory activity on hMAO-B and 
anti-parkinsonian activity in in vivo models of PD. It is 
important to continue studying this coumarin analogue 
because it could be a possible anti-parkinsonian agent.
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